New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 15mg - film coated tablet - 15 mg - active: rivaroxaban 15mg excipient: croscarmellose sodium hypromellose   iron oxide red lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age >= 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 20mg - film coated tablet - 20 mg - active: rivaroxaban 20mg excipient: croscarmellose sodium hypromellose   iron oxide red lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age >= 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 116.4mg equivalent to ciprofloxacin 100 mg, as monohydrate - film coated tablet - 100 mg - active: ciprofloxacin hydrochloride 116.4mg equivalent to ciprofloxacin 100 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 291mg equivalent to ciprofloxacin 250 mg, as monohydrate - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291mg equivalent to ciprofloxacin 250 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 582mg equivalent to ciprofloxacin 500 mg, as monohydrate - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582mg equivalent to ciprofloxacin 500 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 873mg equivalent to ciprofloxacin 75 0mg, as monohydrate - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873mg equivalent to ciprofloxacin 75 0mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - sorafenib tosilate 274mg equivalent to sorafenib 200 mg; sorafenib tosilate 274mg equivalent to sorafenib 200 mg - film coated tablet - 200 mg - active: sorafenib tosilate 274mg equivalent to sorafenib 200 mg excipient: croscarmellose sodium hypromellose   iron oxide red macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide active: sorafenib tosilate 274mg equivalent to sorafenib 200 mg excipient: croscarmellose sodium hypromellose   iron oxide red macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - · nexavar is indicated for the treatment of patients with advanced renal cell carcinoma (rcc).

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 10 g - oral suspension - 100 mg/ml - active: ciprofloxacin 10 g excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin - oral suspension - 50 mg/ml - active: ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) - solution for infusion - 2 mg/ml - active: ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) excipient: hydrochloric acid lactic acid sodium chloride water for injection - infections of the lower respiratory tract. in the treatment of outpatients with pneumonia due to pneumococcus, ciprofloxacin should not be used as a medicine of first choice. ciprofloxacin can be regarded as a suitable treatment for pneumonias caused by klebsiella, enterobacter, proteus, e. coli, pseudomonas, haemophilus, branhamella, legionella, and staphylococcus.